Candesartan

證據等級: L5

預測適應症: 10 個

Candesartan: From Hypertension to Migraine Disorder

One-Sentence Summary

Candesartan is an angiotensin II type 1 receptor blocker (ARB) primarily established for the treatment of hypertension and heart failure. The TxGNN model predicts it may be effective for Migraine Disorder prevention, with 3 relevant clinical trials (including a large Phase 2 multicentre RCT completed in 2024) and 20 publications — including a 2025 Lancet Neurology RCT — currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Hypertension / Heart failure
Predicted New Indication	Migraine Disorder (Episodic Migraine Prevention)
TxGNN Prediction Score	99.97%
Evidence Level	L2
Australia Market Status	Not currently listed on the ARTG
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Candesartan is an angiotensin II type 1 receptor (AT1R) blocker. By selectively antagonising AT1R, it prevents angiotensin II from exerting its vasoconstrictive and pro-inflammatory effects. While currently detailed mechanism of action data from DrugBank is unavailable, the biological rationale for migraine prevention is well-supported by the existing literature.

The renin-angiotensin-aldosterone system (RAAS) is implicated in migraine pathophysiology through several pathways. AT1R antagonism can suppress neurogenic inflammation by reducing calcitonin gene-related peptide (CGRP) release, raise the threshold for cortical spreading depression (the electrophysiological correlate of migraine aura), and stabilise cerebrovascular tone — all of which are recognised targets in migraine prevention. Animal studies have demonstrated that RAAS activation lowers the cortical spreading depression threshold, and genetic research has linked ACE insertion/deletion polymorphisms to individual migraine susceptibility.

This mechanistic plausibility is directly supported by clinical evidence: two earlier Phase 2 randomised controlled trials (Tronvik 2003 and Stovner 2014) demonstrated meaningful reductions in migraine frequency with candesartan 16 mg/day. The largest trial to date (NCT04574713, n=450, completed 2024) sought to confirm these findings in a multicentre, binational, placebo-controlled design, with results published in The Lancet Neurology in 2025 (PMID 40975098). Multiple international clinical guidelines (AAN, ACP, Canadian Headache Society) already list candesartan as a migraine prophylaxis option, further supporting the reasonableness of this TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT04574713	Phase 2	Completed	450	Multicentre, binational, triple-blind, placebo-controlled RCT evaluating candesartan 8 mg and 16 mg/day for episodic migraine prevention. Results published in Lancet Neurology 2025 (PMID 40975098). Strongest and largest direct evidence for this indication.
NCT00884663	Phase 2/3	Completed	72	Three-arm double-blind RCT comparing candesartan vs propranolol vs placebo for migraine prophylaxis. Rigorous head-to-head design; results published in Cephalalgia (Stovner 2014).
NCT04138316	Observational	Completed	85	Prospective observational study (CandeSpartan) assessing response predictors and tolerability of candesartan in patients with episodic or chronic migraine who had failed ≥3 prior preventive drugs. Results published in Cephalalgia 2024 (PMID 38663908).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40975098	2025	RCT	The Lancet. Neurology	Candesartan vs placebo Phase 2 RCT (n=450): evaluated safety, tolerability, and efficacy for episodic migraine prevention. Primary landmark paper for this repurposing direction.
38057728	2023	Systematic Review	J Headache Pain	Network meta-analysis of pharmacological interventions for chronic migraine in adults; positions candesartan within the preventive treatment landscape.
37350141	2023	Systematic Review	Cephalalgia	Systematic review and meta-analysis of blood pressure-lowering medications for episodic migraine prevention, including ARB class evidence.
39899861	2025	Clinical Practice Guideline	Annals of Internal Medicine	American College of Physicians clinical guideline for pharmacologic prevention of episodic migraine in outpatient settings; addresses candesartan’s role.
38663908	2024	Observational Cohort	Cephalalgia	CandeSpartan study: effectiveness, tolerability, and response predictors for candesartan in real-world migraine practice (PMID corresponds to NCT04138316).
33589682	2021	Retrospective Cohort	Scientific Reports	Real-world effectiveness and tolerability of candesartan in migraine (n=all patients, April 2008–February 2019); explores predictors of patient response.
40571531	2025	Scoping Review	Clinical Therapeutics	Comprehensive scoping review of candesartan for migraine management; summarises the growing evidence base for this ARB in headache disorders.
31515634	2019	Systematic Review	Current Pain and Headache Reports	Systematic review of ACE inhibitors and ARBs for prophylactic migraine treatment in adults; identifies research gaps and provides guidance for future trials.
30600979	2019	Review	American Family Physician	Comprehensive review of migraine headache prophylaxis including candesartan; notes that <13% of eligible patients take prophylactic medications.
18759728	2008	Review	Medical Journal of Australia	Australian-context review of migraine prophylaxis options; explicitly identifies candesartan as a drug “gaining favour” with “reasonably good but limited” evidence — directly relevant to Australian prescribers.

Australia Market Information

Candesartan is not currently listed on the Australian Register of Therapeutic Goods (ARTG) based on available data. No ARTG entries were identified in the regulatory search conducted on 9 March 2026.

Note for Prescribers: Candesartan cilexetil (the prodrug formulation) is marketed in many comparable jurisdictions (UK, USA, Canada, Japan) under brand names such as Atacand. A discrepancy between this regulatory data and known international availability suggests a data gap in the ARTG lookup. Prescribers should verify current ARTG status directly via the TGA ARTG search portal before clinical use.

Safety Considerations

Detailed TGA-approved Product Information (PI) warnings and contraindications were not available in the Evidence Pack. However, the literature search identified the following class-level safety signals relevant to candesartan and ARBs generally:

Pregnancy risk (Fetopathy): Multiple published case series (PMID 15669052, 18412789, 21271514) document oligohydramnios, fetal growth retardation, and pulmonary hypoplasia associated with ARB use during pregnancy — a critical contraindication that must be addressed in any prescribing protocol for women of childbearing age.
Pulmonary adverse events: A case report (PMID 22890134) describes diffuse alveolitis temporally associated with candesartan-hydrochlorothiazide, which resolved on discontinuation.

For complete safety information including all contraindications, warnings, drug interactions, and special population guidance, please refer to the TGA-approved Product Information (PI) for candesartan cilexetil. Given the absence of ARTG registration, the equivalent PI from a comparable regulator (e.g., UK MHRA, Health Canada) should be reviewed as an interim reference.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 2 multicentre RCT (NCT04574713, n=450, Lancet Neurology 2025) provides direct evidence for candesartan in episodic migraine prevention, corroborated by a second completed Phase 2/3 RCT (NCT00884663), real-world cohort data, multiple systematic reviews, and endorsement in international clinical guidelines from AAN, ACP, and the Canadian Headache Society. The mechanistic basis (AT1R-mediated CGRP suppression and cortical spreading depression threshold modulation) is biologically coherent and well-supported. The evidence level (L2) justifies advancing beyond hypothesis, but confirmation in a Phase 3 trial and TGA regulatory pathway remains outstanding.

To proceed, the following is needed:

Regulatory pathway clarification: Verify ARTG status; if candesartan cilexetil is indeed not registered in Australia, determine whether a Section 19A import approval, Special Access Scheme (SAS), or new TGA submission is required for off-label prescribing in migraine.
Detailed mechanism of action data (MOA): Obtain full DrugBank entry to confirm AT1R selectivity and secondary pharmacological targets relevant to migraine neurobiology.
TGA Product Information (PI): Download and review the PI or comparable regulatory document to complete the safety assessment, particularly for contraindications (pregnancy), drug interactions (potassium-sparing agents, NSAIDs, lithium), and renal function monitoring requirements.
Phase 3 RCT evidence: The 2025 Lancet Neurology paper from NCT04574713 is Phase 2; a full Phase 3 confirmatory trial would be required to support TGA indication registration.
Local population considerations: Assess applicability to the Australian migraine population, including co-morbid hypertension prevalence, where candesartan could offer dual therapeutic benefit.
Pharmacoeconomic analysis: Given availability of subsidised prophylactics on the PBS (e.g., propranolol, topiramate), a cost-effectiveness comparison should be conducted before any PBS listing proposal.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.